Stocks and Investing
Stocks and Investing
Wed, May 18, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, May 17, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Andrew Berens Maintained (AGIO) at Hold with Increased Target to $33 on, May 17th, 2022
Andrew Berens of SVB Leerink, Maintained "Agios Pharmaceuticals, Inc." (AGIO) at Hold with Increased Target from $30 to $33 on, May 17th, 2022.
Andrew has made no other calls on AGIO in the last 4 months.
There are 4 other peers that have a rating on AGIO. Out of the 4 peers that are also analyzing AGIO, 0 agree with Andrew's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Andrew
- Salveen Richter of "Goldman Sachs" Maintained at Strong Sell with Decreased Target to $23 on, Monday, March 7th, 2022
- Michael King of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $96 on, Thursday, March 3rd, 2022
- Kennen MacKay of "RBC Capital" Maintained at Buy with Increased Target to $67 on, Friday, February 25th, 2022
- John Newman of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $44 on, Wednesday, February 16th, 2022
Contributing Sources